Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy (FAP): Updated Safety and Efficacy Najat Khan, Ph.D ., Chief R&D and Chief Commercial Officer and incoming CEO and ...

Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present ...

Recursive Agents implements a three-phase iterative refinement architecture where LLM agents (instances of Classes) critique and improve their own outputs. Unlike single-pass systems, each agent ...

Abstract: Sentiment analysis, a subset of natural language processing, focuses on identifying the emotional tone within text computationally. This study reviews machine learning algorithms used in ...

Abstract: The United Nations’ 13th Sustainable Development Goal (SDG) aims to tackle climate change and its consequences. Understanding the SDGs’ development is critical for policymakers, especially ...